Literature DB >> 24277437

Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil.

Sergio Monteiro de Almeida1, Clea Elisa Ribeiro, Ana Paula de Pereira, Jayraan Badiee, Mariana Cherner, Davey Smith, Ingrid Maich, Sonia Mara Raboni, Indianara Rotta, Francisco Jaime Barbosa, Robert K Heaton, Anya Umlauf, Ronald J Ellis.   

Abstract

HIV-1 clade C isolates show reduced Tat protein chemoattractant activity compared with clade B. This might influence neuropathogenesis by altering trafficking of monocytes into the CNS. A previous study suggested low rates of HIV-associated dementia in clade C-infected individuals. The present study evaluated neurocognitive impairment rates in clade B- and C-infected individuals from the same local population. HIV+ and HIV- participants were recruited from the same geographic region in Southern Brazil. We evaluated neuropsychological (NP) impairment using a screening instrument (the International HIV Dementia Scale (IHDS)), as well as a Brazilian Portuguese adaptation of a comprehensive battery that has demonstrated sensitivity to HIV-associated neurocognitive disorders (HAND) internationally. NP performance in controls was used to generate T scores and impairment ratings by the global deficit score (GDS) method. Clade assignments were ascertained by sequencing pol and env. Blood and cerebrospinal fluid were collected from all HIV+ participants. HIV+ and HIV- participants were comparable on demographic characteristics. HIV+ participants overall were more likely to be impaired than HIV- by the IHDS and the GDS. Clade B- and C-infected individuals were demographically similar and did not differ significantly in rates of impairment. The prevalence of pleocytosis, a marker of intrathecal cellular chemotaxis, also did not differ between clade B and C infections. Clade B and C HIV-infected individuals from the same geographic region, when ascertained using comparable methods, did not differ in their rates of neurocognitive impairment, and there was no evidence of differences in CNS chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277437      PMCID: PMC3923762          DOI: 10.1007/s13365-013-0215-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  14 in total

1.  Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine.

Authors:  Udaykumar Ranga; Raj Shankarappa; Nagadenahalli B Siddappa; Lakshmi Ramakrishna; Ramalingam Nagendran; Marthandan Mahalingam; Anita Mahadevan; Narayana Jayasuryan; Parthasarathy Satishchandra; Susarla K Shankar; Vinayaka R Prasad
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Initial validation of a screening battery for the detection of HIV-associated cognitive impairment.

Authors:  Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  Clin Neuropsychol       Date:  2004-05       Impact factor: 3.535

3.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

4.  HIV TAT forms pores in membranes by inducing saddle-splay curvature: potential role of bidentate hydrogen bonding.

Authors:  Abhijit Mishra; Vernita D Gordon; Lihua Yang; Robert Coridan; Gerard C L Wong
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Phenotypic susceptibility to antiretrovirals among clades C, F, and B/F recombinant antiretroviral-naive HIV type 1 strains.

Authors:  Maria Cecilia A Sucupira; Patricia Munerato; Jussara Silveira; André F Santos; Luiz Mário Janini; Marcelo A Soares; Ricardo Sobhie Diaz
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

6.  Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.

Authors:  Lucette A J Cysique; Paul Maruff; Bruce J Brew
Journal:  Neurology       Date:  2006-05-09       Impact factor: 9.910

7.  Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96).

Authors:  P Satishchandra; A Nalini; M Gourie-Devi; N Khanna; V Santosh; V Ravi; A Desai; A Chandramuki; P N Jayakumar; S K Shankar
Journal:  Indian J Med Res       Date:  2000-01       Impact factor: 2.375

8.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

9.  HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda.

Authors:  Ned Sacktor; Noeline Nakasujja; Richard L Skolasky; Mona Rezapour; Kevin Robertson; Seggane Musisi; Elly Katabira; Allan Ronald; David B Clifford; Oliver Laeyendecker; Thomas C Quinn
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

10.  Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV.

Authors:  Steven Paul Woods; Julie D Rippeth; Alan B Frol; Joel K Levy; Elizabeth Ryan; Vicki M Soukup; Charles H Hinkin; Deborah Lazzaretto; Mariana Cherner; Thomas D Marcotte; Benjamin B Gelman; Susan Morgello; Elyse J Singer; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-09       Impact factor: 2.475

View more
  31 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Francisco Jaime Barbosa; Rujvi Kamat; Ana Paula de Pereira; Sonia Mara Raboni; Indianara Rotta; Clea Elisa Ribeiro; Mariana Cherner; Ronald J Ellis; Joseph Hampton Atkinson
Journal:  J Neurovirol       Date:  2016-07-18       Impact factor: 2.643

3.  A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.

Authors:  J A Joska; J Witten; K G Thomas; C Robertson; M Casson-Crook; H Roosa; J Creighton; J Lyons; J McArthur; N C Sacktor
Journal:  AIDS Behav       Date:  2016-08

4.  Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis.

Authors:  Knut A Hestad; Jonathan Chinyama; Menon J Anitha; Mary S Ngoma; J Allen McCutchan; Donald R Franklin; Robert K Heaton
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

5.  Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B.

Authors:  Sergio M de Almeida; Indianara Rotta; Yanxin Jiang; Xiao Li; Sonia M Raboni; Clea E Ribeiro; Davey Smith; Michael Potter; Florin Vaida; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

6.  Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics.

Authors:  Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-09-07       Impact factor: 2.643

7.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

Review 8.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

9.  White matter fiber bundle lengths are shorter in cART naive HIV: an analysis of quantitative diffusion tractography in South Africa.

Authors:  Jodi M Heaps-Woodruff; John Joska; Ryan Cabeen; Laurie M Baker; Lauren E Salminen; Jacqueline Hoare; David H Laidlaw; Rachel Wamser-Nanney; Chun-Zi Peng; Susan Engelbrecht; Soraya Seedat; Dan J Stein; Robert H Paul
Journal:  Brain Imaging Behav       Date:  2018-10       Impact factor: 3.978

10.  International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.

Authors:  K Robertson; H Jiang; S R Evans; C M Marra; B Berzins; J Hakim; N Sacktor; M Tulius Silva; T B Campbell; A Nair; J Schouten; J Kumwenda; K Supparatpinyo; S Tripathy; N Kumarasamy; A la Rosa; S Montano; A Mwafongo; C Firnhaber; I Sanne; L Naini; F Amod; A Walawander
Journal:  J Neurovirol       Date:  2016-01-05       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.